Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Section of Dermatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Pediatr Dermatol. 2022 Mar;39(2):291-294. doi: 10.1111/pde.14980.
Dupilumab is a fully humanized monoclonal antibody that suppresses Th2-mediated inflammation by inhibiting signaling of interleukin-4 and interleukin-13 through the interleukin-4 alpha receptor subunit, and is approved by the FDA for the treatment of moderate to severe atopic dermatitis (AD) in children 6 years of age and older. While initial data from phase 2 trials in children less than 6 years are promising, dupilumab use in children less than 6 months of age is not well studied. Here we present a case of a 5-month-old boy with severe primary AD, eosinophilia, hypogammaglobulinemia, and poor weight gain, who was successfully treated with dupilumab and experienced no serious adverse effects. To our knowledge, this is the youngest patient to receive dupilumab to date.
度普利尤单抗是一种全人源化单克隆抗体，通过抑制白细胞介素-4 受体亚基抑制白细胞介素-4 和白细胞介素-13 的信号传导，从而抑制 Th2 介导的炎症，已被 FDA 批准用于治疗 6 岁及以上儿童中重度特应性皮炎（AD）。虽然在 6 岁以下儿童的 2 期临床试验中最初的数据令人鼓舞，但对 6 个月以下儿童使用度普利尤单抗的研究还不够充分。在这里，我们报告了一例 5 个月大的男孩患有严重的原发性 AD、嗜酸性粒细胞增多症、低丙种球蛋白血症和体重增长不良，他成功地接受了度普利尤单抗治疗，且没有出现严重的不良反应。据我们所知，这是迄今为止接受度普利尤单抗治疗的最小患者。
